Evolution of Model Systems for Toxicology, Drug Screening, and Disease Modeling

This eBook provides a primer on the history, current state, and future use of cell-based 2-D and 3-D model systems for toxicology, drug screening, and disease modeling. Included are chapters on primary cells, cell lines, stem cells, 3-D cell culture models, and more complex tissue and organ modeling systems.

Key Topics

  • History of primary and cell lines for toxicology
  • Pluripotent stem cell models
  • 2-D vs. 3-D cell culture
  • Organoid benefits and challenges
  • MimEX 3-D Tissue Model Systems*
  • Future models and challenges

Interactive content and useful infographics:

  • ADME/Tox specifications
  • Commonly-used cell lines, categorized by organ
  • 2-D vs. 3-D model systems
  • Organoid reagent guide
  • MimEX 3-D Tissue Model Systems advantages
 
 

* Portions of this product are covered by a license to intellectual property owned by, or licensed to, Multiclonal Therapeutics, Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right under these intellectual property rights to use this product for research purposes only. The purchase of this product does not include any right to use this product or components of this product for resale, for drug discovery intended for commercial gain, for the generation of cells or tissues intended for transplantation in human patients, or for any other commercial purposes, including without limitation, provision of services to a third party, generation of commercial databases, or as a diagnostic or therapeutic. Multiclonal Therapeutics, Inc., reserves all other rights under these rights. For information on purchasing a license to the intellectual property for uses other than in conjunction with this product or to use this product for purposes other than research, please contact Multiclonal Therapeutics, Inc. at licensing@multiclonaltherpaeutics.com.

MimEX eBook

Download eBook

I’m interested in these model systems
(check all that apply):